0
MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, today announced that the European authorities have recommended the granting of a marketing authorization for the veterinary medicinal product PORCILIS® Lawsonia, an intramuscular vaccine against Lawsonia intracellularis for piglets.
PORCILIS® Lawsonia will be indicated for the active immunization of pigs from 3 weeks of age to reduce: diarrhoea, loss of daily weight gain, intestinal lesions, bacterial shedding and mortality caused by Lawsonia intracellularis infection. PORCILIS® Lawsonia will also be approved for mixing with PORCILIS® PCV M Hyo, providing the opportunity for protection against three major diseases affecting pigs in a single intramuscular vaccination: Lawsonia intracellularis, porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo).
Lawsonia intracellularis is a bacterium that causes ileitis, a gastrointestinal disease also known as porcine proliferative enteropathy. As one of the most common gastrointestinal problems in global swine production, ileitis affects pigs’ growth and development, resulting in a sizeable negative economic impact. The disease is present on 80% to 100% of European farms.
Following the positive outcome of the decentralized procedure, European Union countries are currently finalizing their national registrations. Detailed product conditions are described in the Summary of Product Characteristics (SPC) and will be translated in all European Union languages for publishing by individual regulatory authorities.
August 12, 2019 – MSD Animal Health
MSD Animal Health